208 related articles for article (PubMed ID: 32847935)
21. Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer.
Lei X; Zhong Y; Huang L; Li S; Fu J; Zhang L; Zhang Y; Deng Q; Yu X
Cell Death Dis; 2020 Apr; 11(4):232. PubMed ID: 32286274
[TBL] [Abstract][Full Text] [Related]
22. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
23. A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions.
Antonescu CR; Agaram NP; Sung YS; Zhang L; Swanson D; Dickson BC
Am J Surg Pathol; 2018 Apr; 42(4):553-560. PubMed ID: 29309307
[TBL] [Abstract][Full Text] [Related]
24. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.
Conte JE; Golden JA; Kipps J; McIver M; Zurlinden E
Antimicrob Agents Chemother; 2004 Oct; 48(10):3823-7. PubMed ID: 15388441
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
Zhao Q; Zhou H; Pesco-Koplowitz L
J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
[TBL] [Abstract][Full Text] [Related]
26. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
27. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
28. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
[TBL] [Abstract][Full Text] [Related]
29. Hedgehog Signaling and Truncated GLI1 in Cancer.
Doheny D; Manore SG; Wong GL; Lo HW
Cells; 2020 Sep; 9(9):. PubMed ID: 32957513
[TBL] [Abstract][Full Text] [Related]
30. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
32. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
[TBL] [Abstract][Full Text] [Related]
34. The anti-cancer effects of itraconazole in epithelial ovarian cancer.
Choi CH; Ryu JY; Cho YJ; Jeon HK; Choi JJ; Ylaya K; Lee YY; Kim TJ; Chung JY; Hewitt SM; Kim BG; Bae DS; Lee JW
Sci Rep; 2017 Jul; 7(1):6552. PubMed ID: 28747628
[TBL] [Abstract][Full Text] [Related]
35. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD; Kim S; Saba NF; Pickens A; Behera M; Fu RW; Rossi MR; Auffermann WF; Torres WE; Bechara R; Deng X; Sun SY; Fu H; Gal AA; Khuri FR
Clin Cancer Res; 2015 Apr; 21(8):1859-68. PubMed ID: 25673697
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Koks CH; Huitema AD; Kroon ED; Chuenyam T; Sparidans RW; Lange JM; Beijnen JH
Ther Drug Monit; 2003 Apr; 25(2):229-33. PubMed ID: 12657919
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation.
Mouton JW; van Peer A; de Beule K; Van Vliet A; Donnelly JP; Soons PA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4096-102. PubMed ID: 16982783
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography.
Ng QS; Goh V
J Thorac Imaging; 2010 May; 25(2):142-50. PubMed ID: 20463533
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
Rudin CM; Brahmer JR; Juergens RA; Hann CL; Ettinger DS; Sebree R; Smith R; Aftab BT; Huang P; Liu JO
J Thorac Oncol; 2013 May; 8(5):619-23. PubMed ID: 23546045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
